Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Genentech's Tecentriq Misses Key Endpoint in Advanced-Stage Ovarian Cancer

share with twitter share with LinkedIn share with facebook
07/13/2020 | 06:13am EDT

By Colin Kellaher

 

Roche Holding AG's Genentech unit on Monday said a phase 3 study of Tecentriq in advanced-stage ovarian cancer missed a main endpoint.

Genentech said the addition of Tecentriq to Avastin, paclitaxel and carboplatin didn't meet its primary endpoint of progression-free survival for the front-line treatment of women with newly diagnosed advanced-stage ovarian cancer.

Genentech said it is disappointed by the study results, adding that ovarian cancer is one of the most aggressive cancers and is difficult to treat in its advanced stages.

The company said data for the overall survival co-primary endpoint are currently immature, and that follow-up will continue until the next planned analysis.

Genentech noted that it has an extensive development program for Tecentriq, including multiple ongoing and planned phase III studies across several cancers.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

share with twitter share with LinkedIn share with facebook
Latest news on ROCHE HOLDING AG
01:00aRoche announces FDA authorisation for the first Epstein-Barr virus quantitati..
GL
08/04ROCHE : gets FDA okay for transplant patients Epstein-Barr virus test
RE
08/04SPARK THERAPEUTICS : Recognized for Fourth-straight Year as One of Philadelphia'..
AQ
08/04ROCHE : Eastern Ontario Regional Laboratory Association (EORLA) and Roche Diagno..
AQ
08/03ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating
MD
08/03Rival drugmakers launch joint trial of medicines for COVID-19
RE
08/03ROCHE : Princeton's Prud'homme and Yang partner with Genentech to decode a key p..
AQ
08/03Rozlytrek, Roche's first tumour-agnostic therapy, approved in Europe for peop..
GL
08/02ROCHE : gets European marketing approval for cancer treatment Rozlytrek
RE
07/31GLOBAL MARKETS LIVE: A flurry of earnings reports, day 3
More news
Financials
Sales 2020 61 774 M 67 670 M 67 670 M
Net income 2020 15 311 M 16 772 M 16 772 M
Net cash 2020 3 476 M 3 807 M 3 807 M
P/E ratio 2020 19,0x
Yield 2020 2,92%
Capitalization 274 B 300 B 300 B
EV / Sales 2020 4,38x
EV / Sales 2021 4,12x
Nbr of Employees 97 735
Free-Float 82,8%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 380,68 CHF
Last Close Price 321,10 CHF
Spread / Highest target 29,9%
Spread / Average Target 18,6%
Spread / Lowest Target 1,21%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG2.26%299 665
JOHNSON & JOHNSON0.93%387 947
PFIZER, INC.-2.02%213 028
MERCK & CO., INC.-10.20%208 339
NOVARTIS AG-15.79%185 171
ABBVIE INC.6.49%169 079